Patents by Inventor Takuya Osada
Takuya Osada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220226666Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.Type: ApplicationFiled: March 21, 2022Publication date: July 21, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 11305131Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: August 29, 2019Date of Patent: April 19, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 11253580Abstract: Disclosed are compositions, methods, and kits for treating a cancer or pre-cancer. In particular, the invention generally relates to cancer vaccines as well as methods of delivering the vaccines. Combination treatments including the vaccines in combination with immunomodulatory agents are also contemplated.Type: GrantFiled: January 9, 2017Date of Patent: February 22, 2022Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 11235043Abstract: Methods of reducing, the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: April 25, 2018Date of Patent: February 1, 2022Assignee: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Patent number: 11207409Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: GrantFiled: May 30, 2018Date of Patent: December 28, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
-
Publication number: 20210330773Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent, such as a checkpoint inhibitor and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: May 24, 2021Publication date: October 28, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Publication number: 20210077606Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: ApplicationFiled: November 19, 2020Publication date: March 18, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20210069309Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: November 19, 2020Publication date: March 11, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10842855Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: July 24, 2018Date of Patent: November 24, 2020Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10842857Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: GrantFiled: July 25, 2018Date of Patent: November 24, 2020Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20200009398Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
-
Patent number: 10487143Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.Type: GrantFiled: October 5, 2017Date of Patent: November 26, 2019Assignee: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10441810Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: February 16, 2017Date of Patent: October 15, 2019Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20190022204Abstract: Disclosed are compositions, methods, and kits for treating a cancer or pre-cancer. In particular, the invention generally relates to cancer vaccines as well as methods of delivering the vaccines. Combination treatments including the vaccines in combination with immunomodulatory agents are also contemplated.Type: ApplicationFiled: January 9, 2017Publication date: January 24, 2019Applicant: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180344824Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: ApplicationFiled: July 25, 2018Publication date: December 6, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180344850Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: ApplicationFiled: May 30, 2018Publication date: December 6, 2018Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Mark DEWHIRST, Neil SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA, Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER
-
Publication number: 20180326030Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180311329Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polyepptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: April 25, 2018Publication date: November 1, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Publication number: 20180282736Abstract: The present inventors provide HER3 vaccine vector compositions and methods of using the same. More specifically, the present inventors demonstrate, in part, that a combination of HER3 vaccine vectors with checkpoint inhibitors suppresses or eliminates cancer cells more effectively than either alone.Type: ApplicationFiled: April 2, 2018Publication date: October 4, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 9956276Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: January 21, 2013Date of Patent: May 1, 2018Assignee: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman